Abbott Halts Sale of Flu Vaccine Business
September 3, 2010, 5:57 am
Abbott Laboratories has called a halt to the sale of its European flu-vaccine unit because of a dissapointing run of initial bids, The Wall Street Journal reported.雅培製藥已叫停出售它的歐洲流感疫苗單位，由於一令人失望的初步收購回合，華爾街日報報導。
Abbott announced it would be selling the business in June and recieved interest from four or five bidders, but offers did not top €500 million ($640 million), which was lower than the company was expecting, The Journal said, citing a person familiar with the matter.
雅培宣布它將會在6月出售業務和收到4或5個收購者的興趣，但提出並不超過€5億美元（6.4億美元），那是低於公司預期，華爾街日報稱，引述熟悉此事的人。
Abbott found itself saddled with the vaccine business when it acquired the drug division of Belgian conglomerate Solvay and was looking to sell it despite the unit’s profit and expected sales of about €200 million this year, The Journal said.
雅培公司發現自己在疫苗業務進退維谷，當它獲得比利時蘇威集團的藥物分工，和正在尋找出售它，儘管該單位的利潤和今年預計約€2億的銷售，該雜誌說。
“After exploring the option to potentially sell Solvay’s vaccine business, Abbott has decided to retain it,” a spokesman for the company told the newspaper.
http://dealbook.blogs.nytimes.com/2010/09/03/abbott-halts-sale-of-flu-vaccine-business/
疫苗死亡和受傷個案狂升因為掩蓋內爆
家庭在作戰 18年後勝訴MMR疫苗損害兒子
沒有留言:
發佈留言